Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma | Zendy

Dirk Schadendorf | Zendy; F. Stephen Hodi | Zendy; Caroline Robert | Zendy; Jeffrey S. Weber | Zendy; Kim Margolin | Zendy; Omid Hamid | Zendy; Debra A. Patt | Zendy; TaiTsang Chen | Zendy; David M. Berman | Zendy; Jedd D. Wolchok | Zendy

Open Access

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

Author(s) -

Dirk Schadendorf,

F. Stephen Hodi,

Caroline Robert,

Jeffrey S. Weber,

Kim Margolin,

Omid Hamid,

Debra A. Patt,

TaiTsang Chen,

David M. Berman,

Jedd D. Wolchok

Publication year - 2015

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.2014.56.2736

Subject(s) - ipilimumab , medicine , melanoma , survival analysis , proportional hazards model , clinical trial , oncology , surgery , cancer , immunotherapy , cancer research

To provide a more precise estimate of long-term survival observed for ipilimumab-treated patients with advanced melanoma, we performed a pooled analysis of overall survival (OS) data from multiple studies.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research